Table 1 Baseline demographic and clinical characteristics for patients recruited pre- and post- recreational cannabis legalization (N = 1390)
Characteristic | Total Sample (N = 1390) | Recruited pre-legalization (n = 602) | Recruited post-legalization (n = 788) | p value |
|---|---|---|---|---|
Age in years; mean (SD) | 39.3 (10.7) | 38.9 (10.4) | 39.6 (10.8) | 0.295 |
Male sex; n (%) | 817 (58%) | 343 (57%) | 474 (60.2%) | 0.222 |
Type of MAT; n (%) | 0.073 | |||
Methadone | 1120 (80.7%) | 498 (82.9%) | 622 (79%) | |
Buprenorphine | 268 (19.3%) | 103 (17.1%) | 165 (21%) | |
Dose (mg/day); median (IQR) | ||||
Methadone | 68 (64) | 65 (61) | 70 (64) | 0.276 |
Buprenorphine | 12 (9.5) | 12 (8) | 10 (10) | 0.097 |
Length of time in treatment (years); median (IQR) | 2 (5.25) | 2 (4.9) | 2.3 (3.5) | 0.756 |
Opioid abstinencea; n (%) | 417 (30%) | 176 (29.2%) | 241 (30.6%) | 0.587 |
Percentage of opioid-positive urine drug screens amongst non-abstainersa; mean (SD) | 22.6 (23.6) | 21.1 (23.3) | 23.7 (23.8) | 0.090 |